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Abstract The proprotein convertase subtilisin/kexin type
9 (PCSK9) has emerged as a promising treatment target to
lower serum cholesterol, a major risk factor of cardiovas-
cular diseases. Gain-of-function mutations of PCSK9 are
associated with hypercholesterolemia and increased risk of
cardiovascular events. Conversely, loss-of-function muta-
tions cause low-plasma LDL-C levels and a reduction of
cardiovascular risk without known unwanted effects on
individual health. Experimental studies have revealed that
PCSK9 reduces the hepatic uptake of LDL-C by increasing
the endosomal and lysosomal degradation of LDL recep-
tors (LDLR). A number of clinical studies have demon-
strated that inhibition of PCSK9 alone and in addition to
statins potently reduces serum LDL-C concentrations. This
review summarizes the current data on the regulation of
PCSK9, its molecular function in lipid homeostasis and the
emerging evidence on the extra-hepatic effects of PCSK9.
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Protein convertase–LDL receptor interaction
The main function of the proprotein convertase subtilisin/
kexin (PCSK) type 9 (PCSK9) is the proteolytic maturation
of secreted proteins such as hormones, cytokines, growth
factors, and cell surface receptors [149]. The name PCSK9
stems from the relation to bacterial subtilisin and yeast
kexin and the presence of nine secretory serine proteases.
PCSK9 is expressed mainly in the liver, the intestine, the
kidney, and the central nervous system [122].
PCSK9 is a 692 amino acid protein with a molecular
weight of 72 kDa that consists of a prodomain (PD), a
catalytic domain and a cysteine- and histidine-rich C-ter-
minal domain (CHRD) [41] (Fig. 1). The best character-
ized function of PCSK9 relates to the binding to LDL-C
receptors (LDLR) in hepatocytes. Pro-PCSK9 (72 kDa) is
synthesized in the endoplasmic reticulum (ER) as is the
precursor form (120 kDa) of the low-density lipoprotein
(LDL) receptor (LDLR). The binding of pro-PCSK9 to the
LDLR in the ER supports the transport of the LDLR from
the ER [163] towards the Golgi complex, where the LDLR
acquires its mature carbohydrate residues (160 kDa).
Trafficking of pro-PCSK9 to the Golgi apparatus depends
on the presence of the protein Sec24A [31]. Within the
Golgi, the pro-domain of pro-PCSK9 is auto-catalytically
cleaved off, but remains non-covalently bound to the
mature PCSK9 assisting the folding of PCSK9, and
blocking its catalytic activity [61]. Binding of pro-PCSK9
to the precursor form of the LDLR promotes PCSK9 auto-
catalytic cleavage [163].
Some of the loss-of-function (LOF) mutations of
PCSK9—as the exchange of amino acids C678X [15] or
S462P [25]—abolish the release of PCSK9 from the ER as
does loss of parts of its PD [49]. On its way through the
Golgi and trans-Golgi complex, PCSK9 co-localizes with
the protein sortilin; in sortilin-knockout mice the plasma
PCSK9 concentration is decreased suggesting that such
protein–protein interaction is required for cellular secretion
of PCSK9 [66]. In healthy humans, circulating PCSK9
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levels directly correlate with plasma sortilin levels [66].
The exchange of amino acids S127R and D124G reduces
secretion of PCSK9 from hepatocytes and increases the
intracellular expression of PCSK9 [72]. It appears that
partial proteolysis of PCSK9 is required prior to its cellular
secretion [36]. Proteolysis of PCSK9 is regulated by
phosphorylation at its residues serine 47 (PD) and serine
688 (CHRD) which occurs by a Golgi casein kinase-like
kinase; an increase in epitope phosphorylation reduces
proteolysis of PCSK9 [45].
Apart from acting as a chaperone to transport the pre-
cursor form of the LDLR from the ER, intracellular PCSK9
plays a role in regulating the expression of the mature
LDLR by inducing intracellular degradation of the LDLR
prior to its transport to the cell surface membrane. Given
the fact that the mature LDLR and PCSK9 are found in the
Golgi complex, it is likely that the LDLR degrading effect
of PCSK9 occurs in or is initiated in the Golgi or trans-
Golgi complex [107, 108]. The post-ER mechanism of
LDLR degradation requires the catalytic activity of PCSK9
[13, 14].
If not degraded intracellularly, the mature LDLR is
transported to the cell surface, where it resides in clathrin-
coated pits because of its interaction with the low-density
lipoprotein receptor adapter protein 1, which may cause
autosomal recessive hypercholesterolemia (ARH). The
LDLR undergoes endocytosis in the presence or absence of
its ligand, entering the endocytic recycling compartment.
The change in pH within this compartment allows disso-
ciation of the LDLR from its ligand, which then becomes
degraded in the lysosome while the LDLR recycles.
The main role of secreted extracellular PCSK9 is to
post-translationally regulate the number of cell surface
LDLR. Secreted PCSK9 binds to the epidermal growth
factor repeat A (EGF-A) region of the LDLR [21, 32, 179].
For such binding, the catalytic activity of PCSK9 is not
required [101, 115], but pH changes and changes in the
positive [70] or negative [71] charges of PCSK9 epitopes
affect its binding affinity to the LDLR [16, 62]. Mutations
in the EGF-A binding domain of the LDLR associated with
familiar hypercholesterolemia increases PCSK9 binding
[114]. The formed PCSK9–LDLR complex is internalized
again by clathrin-mediated endocytosis [124, 130] and the
complex is then routed to the sorting endosome/lysosome
via a mechanism that does not require ubiquitination [172],
but might involve interaction of the cytosolic tail of PCSK9
with the amyloid precursor protein like protein 2 [44]. At
the acidic pH of the endosome/lysosome, an additional
interaction between the ligand-binding domain of the
LDLR and the C-terminal domain of PCSK9 occurs [49,
142]; as a consequence PCSK9 remains bound to the
LDLR and the LDLR fails to adopt a closed conformation
which is required for LDLR recycling. The failure of the
LDLR to recycle appears to also involve ectodomain
cleavage by a cysteine cathepsin in the sorting endosome
[97]. Thus, by binding to the LDLR, PCSK9 disrupts the
recycling of the LDLR leading to its degradation and
subsequently a reduced number of available LDLRs.
LDLR lacking its cytoplasmic domain are also degraded by
PCSK9 [162] (Fig. 2).
PCSK9 undergoes self-assembly and forms PCSK9
dimers or trimers which have greater LDLR degrading
activity [53]. One of the gain-of-function (GOF) mutations
of PCSK9 (D374Y) is characterized by an enhanced
PCSK9 self-assembly [53]. The main route of PCSK9
elimination is through LDLR binding [167], although
LDLR-independent mechanisms of PCSK9 clearance must
exist [24]. Up to 30 % of PCSK9 is bound to LDL-C in
mice [55, 167] and normolipidemic subjects [84]. In mice,
PCSK9 is also bound to high-density lipoprotein (HDL)
[55]. For the binding of PCSK9 to LDL-C the amino res-
idues 31–52 of the PD are required [84].
PCSK9 is cleaved by furin as well as protein convertases
(PC) 5/6 [15] between the amino acids Arg 218 and Gln
219 [52], and both forms of PCSK9 can be measured in
human plasma [67]. Furin-cleaved PCSK9 (55 kDa) is still
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Fig. 1 The structure of PCSK9 contains a signal peptide (SP, amino
acids 1–30), a prodomain (Pro, amino acids 31–152), a catalytic
domain and the C-terminal domain. The cleavage of the prodomain is
required for PCSK9 folding and maturation. The location of the
aspartic acid (D), histidine (H) and serine (S) comprising the catalytic
triad and the site of binding of the single N-linked sugar (Asn533) are
shown. The oxyanion hole is located at Asn317. Mutations associated
with elevated plasma levels of LDL-C are depicted at the top (blue),
mutations leading to reduced LDL-C at the bottom (green). The
asterisk indicates mutations associated with elevated plasma LDL-C
levels found only in families who also have mutations in the LDL
receptor (modified from [75])
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active and binds to the LDLR, however, with a twofold
reduced activity [104]. Indeed, injection of furin-cleaved
PCSK9 into mice results in increased LDL-C, as LDLR are
downregulated [104].
PCSK9 binds to a variety of other proteins (for review,
see [178]), one of them being annexin A2 which is present
in the nucleus, the cytosol and the cell membrane in a
variety of cells. The N-terminal repeat R1 of annexin 2
binds to the CHRD region of PCSK9 and inhibits its
extracellular LDLR degrading activity [109]. In annexin
A2 knockout mice plasma PCSK9 levels are doubled
resulting in reduced LDLR expression and an increase in
LDL-C [151]; thus annexin A2 is viewed as endogenous
inhibitor of PCSK9 [109].
In summary, PCSK9 regulates the concentration of cir-
culating low-density lipoproteins by enhancing the degra-
dation of the hepatic LDLR that is required for hepatic
LDL-C clearance.
Plasma concentration of PCSK9
The plasma concentration of PCSK9 follows a diurnal
rhythm similar to cholesterol synthesis [28], with an
increased plasma concentration in the morning and a lower
concentration in the afternoon [125]. The plasma PCSK9
concentration is higher in women compared to men [90],
and the PCSK9 concentrations decrease with age in men,
but increase in women [11], most likely because elevated
estrogen levels reduce PCSK9 expression [126]. Plasma
PCSK9 concentration varies over a 50 [34]–100 [90] fold
range [30–3,000 ng/ml] and plasma PCSK9 concentration
correlates to plasma LDL-C concentration [4, 90] even in
newborn infants [6]; in adults a 100 ng/ml increase in the
plasma PCSK9 concentration will increase LDL-C by
0.20–0.25 mmol/l [92]. Lipid apheresis reduces plasma
PCSK9 levels by 50 % [168], removing both the mature
and the furin-cleaved form of PCSK9 [74].
Regulation of PCSK9 gene expression
A number of transcription factors or cofactors regulate the
PCSK9 gene expression (Fig. 3), including sterol-response
element binding proteins (SREBP-1/2). Since the PCSK9
gene is regulated by sterols through SREBP2, low dietary
cholesterol concentrations potently suppresses its expres-
sion and PCSK9 protein levels decrease in the course of
fasting and increase after feeding in animals [175] and
humans [23]. SREBP2 also controls LDLR expression.
SREBP1 expression in hepatocytes is increased by
insulin resulting in increased PCSK9 expression [39].
However, insulin can also activate the mammalian target of
rapamycin complex 1 (mTORC1)/protein kinase d pathway
thereby inhibiting hepatocyte nuclear factor 1a (HNF1a)
resulting in less PCSK9 expression in hepatocytes [2].
Indeed, in HepG2 cells, hyperinsulinemia decreases
PCSK9 expression, an effect which is also observed in
post-menopausal obese women [9]. On the contrary, in
healthy men 24 h hyperinsulinemia did not alter plasma
PCSK9 concentrations [80] and PCSK9 expression is





















Fig. 2 Schematic overview about the
cellular regulation of PCSK9 and
LDLR expression
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Thus, the overall effect of insulin on PCSK9 expression
appears to be neutral.
Peroxisome proliferator-activated receptor (PPAR) reg-
ulates PCSK9 expression: PPARa reduces PCSK9 pro-
moter activity thereby attenuating PCSK9 expression,
while at the same time PPARa enhances furin/PC5/6
expression leading to increased cleavage of PCSK9 [85].
On the contrary, PPARc increases PCSK9 expression in
hepatocytes [50].
Other transcription factors or factors are the farnesoid X
receptor (FXR, activated by bile acids, reduces PCSK9
expression) [93], the liver X receptor (LXR, activated by
oxysterols, increases PCSK9 expression) [39, 148], and
histone nuclear factor P (HINFP, increases PCSK9
expression) [100].
Also sirtuins 1 and 6 (SIRT1/6), critical histone
deacetylases, suppress the PCSK9 gene [166], reduce
PCSK9 secretion and increase hepatocyte LDLR expres-
sion [117] thereby modifying LDL-C homeostasis. Finally,
the adipose tissue-derived adipokine resistin increases the
PCSK9 expression and reduces LDLR expression in
hepatocytes [116].
Ongoing studies will be instrumental for the under-
standing of the importance of the regulators of PCSK9
gene expression for serum LDL-C concentrations. In
addition, further research is needed to address the expres-
sion of PCSK9 and its function in different compartments
(e.g. blood, liver and intestine).
PCSK9 and inducible degrader of LDLR (IDOL)
IDOL is another protein which involved in the internali-
zation and degradation of the LDLR [77, 144]. IDOL binds
to the C-terminus of the LDLR [147, 148] and stimulates
clathrin-independent endocytosis of the LDLR [147].
IDOL, which is activated through the LXR employs the
endosomal sorting complex required for transport to traffic
LDLR to the lysosomes [147]. IDOL can also stimulate
SREBP2 thereby increasing PCSK9 expression again
reducing LDLR expression. Individuals carrying an IDOL
mutation (pArg266X) which results in a complete loss of
IDOL function exhibit low serum LDL-C concentrations
[156].
Drug-induced changes in PCSK9 expression
Given the number of transcription factors and co-factors
regulating the PCSK9 gene it appears obvious that a
number of drugs will affect PCSK9 expression (Table 1).
Statins increase the transcription factor SREBP2 [7]
thereby increasing PCSK9 expression [7, 18, 138] dose-
dependently [64] also in diabetic patients (otherwise hav-
ing normal PCSK9 levels, see above) [29, 40, 120]. More
recently, statins have been shown to increase HNF1a
expression in hepatocytes, thereby increasing PCSK9














Fig. 3 Activation of PCSK9 expression can be mediated by activation
of insulin receptors (Ins-R) and subsequent activation of the sterol-
response element binding protein (SREBP) 1 and mammalian target of
rapamycin (mTOR) pathways. Reduction of PCSK9 expression can be
achieved by peroxisome proliferator-activated receptor alpha
(PPARa) and activation of SREBP2. Secretion of PCSK9 can be
attenuated by annexin A2. Plasma concentration of PCSK9 can be
reduced by PPARa-dependent cleavage (requiring furin). High
concentrations of PCSK9 down-regulate LDLR expression and favor
the formation of oxidized (ox)-LDL. See text for more details
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Statins not only enhance the monomeric but also the
heterodimeric form of PCSK9 [123]. The increase in
PCSK9 expression following statin treatment is correlated
to the statin-induced LDL-C decrease [10], and can be
reversed by mevalonate treatment [51] or resistin treatment
[116]. Such co-treatment therefore could enhance the LDL-
C reducing effect of statins.
Fibrates activate PPARa thereby affecting PCSK9
expression [85]. Indeed, fibrates reduce PCSK9 expression
in hepatocytes [110] and in patients [91]. However, the
latter finding is controversial since fibrate treatment
increased PCSK9 in another short-term patient study [169];
this discrepant finding can potentially be explained by the
LDL-C lowering effect of fibrates leading to an increased
PCSK9 expression (for review, see [12]).
Ezetimibe does not increase PCSK9 per se in healthy
men [18]. However, ezetimibe through its plasma LDL-C
concentration reducing effect might lead to a secondary
increase of PCSK9 expression as measured in cynomolgus
monkeys [68].
Cholesterylester transfer protein (CETP) inhibitors, in
contrast downregulate PCSK9 and LDLR expression through
decreases in SREBP2 expression in hepatocytes [47].
Glitazones activate the extracellular-regulated kinases
(ERK) 1 and 2 resulting in phosphorylation of PPARc
thereby reducing its activity; as PPARc increases PCSK9
mRNA and protein expression in the liver, glitazones
attenuate secretion of PCSK9 from hepatocytes [50].
Rapamycin, as an immunosuppressant, attenuates
mTORC1 activation thereby increasing HNF1a activity
and subsequently PCSK9 expression [2].
Berberine treatment decreases PCSK9 in hepatocytes
associated with an inhibition of the transcription factor
HNF1a [26, 99]. Interestingly, in in vivo studies, berberine
treatment reduces dyslipidemia induced by LPS treatment
which was associated with a reduction in the plasma
PCSK9 concentration [177].
Disease-induced changes of PCSK9 expression
Inflammation stimulates PCSK9 expression in hepatocytes
[54] and the plasma PCSK9 concentration is correlated to
white blood cell count [102] and fibrinogen concentration
[181] in patients. In patients with an acute myocardial
infarction, the plasma PCSK9 concentration is elevated
compared to stable coronary artery disease patients [5].
Similarly in proteinuric patients [87] and those with a
nephrotic syndrome [79] an increase in plasma PCSK9
concentration occurs; part of this effect, however, might
relate to the statin treatment of these patients.
PCSK9 mutations and LDL-C concentration
Alterations in the PCSK9 gene and/or PCSK9 GOF muta-
tions are responsible in part for familiar hypercholesterol-
emia (FH) [106], including the autosomal dominant form.
GOF mutations of PCSK9 [1, 15, 72] lead to hypercholes-
terolemia while non-sense mutations [1] or LOF-mutations
[15, 17, 34, 45] reduce the LDL-C concentration (Fig. 1).
GOF mutations are sometimes related to reduced furin
cleavage of PCSK9 [52] while LOF-mutations relate to lack
of PCSK9 phosphorylation and subsequent increased pro-
teolysis [45]. For review, please refer to [170].
PCSK9 and cardiovascular disease
The GOF-mutation (D374Y) of PCSK9 causes severe
hypercholesterolemia and development of profound ath-
erosclerotic lesions in mice [137] and pigs [3]. PCSK9
overexpression increases LDL-C concentration in mice and
accelerates the development of atherosclerosis, the latter
being absent in LDLR-knockout mice [41]. On the contrary,
development of atherosclerosis is slowed down by
Table 1 Drugs affecting
PCSK9 expression
Direct direct effect through
modulation of TF, indirect
indirect through reduction of
LDL-cholesterol and subsequent
activation of TF, SREBP sterol-
response element binding
protein, HNF1a hepatocyte
nuclear factor 1a, PPAR
peroxisome proliferator-










Statins ? ? Increased SREBP2; HNF1a
Fibrates ? ? Direct effect: reduced; PPARa
Indirect effect: increased SREBP2
Ezetimibe – ? Indirect effect: increased SREBP2
Insulin ? – Increased SREBP1
Reduced HNF1a
Glitazones ? – Reduced PPARc
Rapamycine ? – Reduced HNF1a
Berberine ? – Reduced HNF1a
Resistin na na Reduced na
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inactivation of the PCSK9 gene in mice [41]. These data
were supported by Ku¨hnast et al. [86] treating mice with
increased atherogenesis with different doses of a PCSK9
inhibitor alone and in combination with atorvastatin. Ali-
rocumab alone dose-dependently decreased serum choles-
terol, reduced atherosclerotic lesion size and improved
plaque morphology. These effects were enhanced when
atorvastatin was added [86] (Fig. 4) but beneficial effects
require both the presence of the LDLR and apoprotein E [8].
Development of atherosclerosis involves endothelial cell
apoptosis and accumulation of foam cells, both of which
can be triggered by oxidized LDL-C (oxLDL-C) [154, 165,
174]. Indeed, oxLDL-C increases PCSK9 expression in
macrophages [165] and the oxLDL-C induced apoptosis is
reduced in human umbilical vein endothelial cells by
silencing PCSK9, an effect being related to less caspase 9
and 3 activation [174]. Also cholesterol uptake of THP-1
macrophages and foam cell formation as well as oxLDL-C/
NFkB- induced inflammation are attenuated by PCSK9
silencing [165] (for review, see [154]).
In line with the above cell and animal experiments, the
plasma PCSK9 concentration correlates with the intima-
media thickness in patients [96], and GOF mutations of
PCSK9 increase not only the LDL-C concentration but also
the intima-media thickness over time compared to normal
subjects [121]. Plasma PCSK9 concentrations are predictive
for 4-5 year major cardiovascular event rate [76] and
PCSK9 serum concentrations correlate with cardiovascular
risk [95]. In patients with stable coronary artery disease
(Fig. 5), higher PCSK9 concentrations were associated with
increased cardiovascular events and with female gender,
hypertension, statin treatment, C-reactive protein, HbA1c,
insulin, total cholesterol and fasting triglycerides, but not
with LDL- or HDL-cholesterol. Interestingly, the associa-
tion of PCSK9 levels with cardiovascular events was
reduced after adjustment for fasting triglycerides [173].
With high-dose statin treatment, however, the predictive
value of PCSK9 is lost [76]. Mutations of PCSK9 leading
to reduced expression and or function of PCSK9 are
associated with a reduced rate of coronary heart disease
[37] (Fig. 6), myocardial infarction [63] and overall car-
diovascular events [143], an effect being more pronounced
in black as compared to white subjects [37].
Other receptors/channels/enzymes affected by PCSK9
Apart from its binding to LDLR, PCSK9 also interacts with
other receptors such as the very low-density lipoprotein
receptor (VLDLR) [88, 127], the LDLR-related protein 1
(LRP1) [27], the apoprotein E receptor (ApoER) as well as
CD81 on hepatocytes (hepatitis C virus receptor) [89] and
CD36 on macrophages (for review, see [154]). Some
interactions of PCSK9 with receptors depend on a EGF-A
binding domain (VLDLR) [152] or require the catalytic
Control
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Fig. 4 Correlation between
average plasma TC and
atherosclerotic lesion area in
APOE*3Leiden.CETP mice
treated with different doses of
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Fig. 5 Number of primary outcome events (cardiovascular death and
unplanned cardiovascular hospitalization) in 504 consecutive patients
with stable coronary artery disease stratified by PCSK9 tertiles after
48 months. Increased PCSK9 serum concentrations correlate with
outcomes. (modified from [173])
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activity of PCSK9 (LRP1). VLDLR and ApoER are also
targeted by IDOL (for review, see [76]).
Lipoprotein (Lp) (a)
Clinical studies show that inhibition of PCSK9 potently
lowers Lp(a), which is a strong cardiovascular risk factor
[59, 159]. Currently, no drug treatment is available that
lowers Lp(a) (with the exeption of nicotinic acid in some
countries). Interestingly, PCSK9 inhibition reduces
Lp(a) in patients with homozygous FH despite their lack or
dysfunction of the LDLR. This effect was observed even in
patients that are LDLR negative [159]. Therefore, the
question arises whether the regulation of Lp(a) by PCSK9
may be independent of the LDLR. From this perspective,
the modulation of VLDLR by PCSK9 appears to be of
great interest since Lp(a) clearance by hepatocytes appears
to depend on VLDLR expression [73]. Thus, reducing
PCSK9 expression or receptor binding activity may
mediate the reduction of Lp(a). The underlying molecular
mechanism(s) are not fully understood. The following
pathways may contribute:
– Reduction of Apo(a) synthesis (in hepatocytes, release
in circulation).
– Reduction of ApoB or assembly (at outer hepatocyte
surface).
– Enhanced removal of Lp(a) in kidney, liver, peripheral
tissues. Potential additional receptors for Lp(a) such as
docking receptors, sorting receptors sortilin, endocytic
receptors (syndecan-1 heparan sulfate proteoglycan).
– Intestinal lipoprotein metabolism (please see below).
Epithelial ENaC
Expression at the cell surface is reduced by PCSK9.
PCSK9—independent from its catalytic activity— the
proteosomal degradation of ENaC prior to its membrane
integration; interestingly and different from other receptor
interactions, PCSK9 does not interfere with membrane-
bound ENaC [153]. It has been speculated that GOF
mutation of PCSK9 will therefore reduce membrane-bound
ENaC expression leading to less sodium reabsorption and
potentially less hypertension in the long-term. However,
the clinical study programs of PCSK9 inhibiting antibodies
have not shown signals of increased blood pressure to date.
Extra-hepatic expression and effects of PCSK9
Intestinal cholesterol absorption
Although the hepatic effects of PCSK9 appear to be the
primary mechanism of action, PCSK9 in intestinal cells
may play a very important role for the lipoprotein
homeostasis. PCSK9 increases the expression of the apical
cholesterol transporter (Niemann Pick C1 like 1, NPC1L1)
in intestine epithelial cells [98]. Furthermore, PCSK9
enhances the intracellular expression of the apoprotein B48
(apoB48) [98, 135] and modifies the activities of the HMG-
CoA reductase (decreased), the Acyl-CoA-Cholesterol-
Cohen J et al. N Engl J Med 2006;354:1264-1272
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Fig. 6 In the Atherosclerosis
Risk in Communities study
(ARIC), sequence variants of
PCSK9 that are associated with
reduced plasma LDL-C are
associated with reduced risk of
coronary heart disease (CHD).
The figure depicts the results of
n = 3363 black subjects: 2.6 %
showed nonsense mutations in
PCSK9; these mutations were
associated with a 28 %
reduction in mean LDL-C and a
88 % reduction in the risk of
CHD. Of the 9,524 white
subjects examined, 3.2 % had a
sequence variation in PCSK9
that was associated with a 15 %
reduction in LDL-C and a 47 %
reduction in the risk of CHD
(P = 0.003) (modified from
[37])
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Transferase (ACAT, decreased) [98] and the microsomal
transfer protein (MTP, increased) [98]. It also reduces the
expression of the LDLR at the basolateral membrane of
intestine epithelial cells [98]. PCSK9 promotes intestinal
overproduction of triglyceride-rich apoB lipoproteins
[135], and a reduction in PCSK9 leads to a reduced apoB48
expression, less triglycerides being transferred to apoB48
(via MTP inhibition) and prolonged storage and less
secretion of triglycerides (via ACAT inhibition) from
intestine epithelial cells. As a consequence postprandial
triglyceridemia is reduced in PCSK9 knockout mice [95].
Furthermore, the transintestinal cholesterol excretion
(TICE)—contributes up to 30 % of fecal neutral sterols
excretion—is modulated by PCSK9. TICE is fuelled by
apoprotein B containing particles such as LDL and also to
a minor extent by HDL. TICE involves the active trans-
porter ATP binding cassette transporter B1 on the apical
membrane of enterocytes and the LDLR at its basolateral
membrane [94]. PCSK9 through decreasing LDLR
expression reduces TICE, as it had no impact in LDLR-
knockout mice [94]. These findings may explain the
correlation of PCSK9 with triglycerides in the serum
[173].
PCSK9 in the brain
PCSK9 was initially discovered as a protein up-regulated
during apoptosis of neurons [150]. PCSK9, that was for-
merly known as NARC-1 is important for brain develop-
ment, especially the cerebellum [128]. Here, PCSK9 is
thought to interact primarily with VLDLR and ApoER
which are coupled to relin signaling and pro-apoptotic
signaling pathways [88], although an interaction of PCSK9
with ApoER in brain tissue was questioned more recently
[105]. PCSK9 is present in the cerebrospinal fluid at
remarkably constant concentrations [33]. Brain tissue
PCSK9 expression is increased with cerebral ischemia [88]
and in brain tissue with signs of neuronal apoptosis [19],
the latter being induced for example by increased oxLDL-
C concentrations [176]. A relation to vascular dementia and
Alzheimer’s disease is controversial, PCSK9 may be
involved in degradation of b-site amyloid precursor protein
(APP)-cleaving enzyme 1 and the generation of amyloid b-
peptide.
The location of the ‘‘loss-of-function’’ single-nucleotide
polymorphism rs11591147 (more commonly called R46L) is
depicted in Fig. 1. In the Atherosclerosis Risk in Communities
study (ARIC), the R46L mutation was associated with lower
LDL-C and a reduced prevalence of peripheral arterial disease
as well as a reduced risk of coronary heart disease [17, 37, 57].
Recently, the effects of LDL-C lowering mediated by
PCSK9 inhibition on cognitive function have become a mat-
ter of debate [http://digitool.library.mcgill.ca/webclient/
StreamGate?folder_id=0&dvs=1420384772483*463]. Juk-
ema et al. therefore assessed the PCSK9 R46Lmutation within
5,777 participants of the PROspective Study of Pravastatin in
the Elderly at Risk (PROSPER) [129]. R46L was associated
with 10–16 % lower LDL-C levels, but was not associated
with cognitive performance, daily activities, or non-cardio-
vascular clinical events. The authors conclude ‘‘that lower
cholesterol levels due to genetic variation in the PCSK9 gene
are not associated with cognitive performance, functional
status, or non-cardiovascular clinical events’’ [129].
PCSK9 in pancreatic ß-cells
PCSK9 and LDLR are also expressed in ß-cells. PCSK9-
knockout mice carry more LDLR and less insulin in the
pancreas, leading to hyperglycemia and glucose intoler-
ance. ß-cell islets of PCSK9-knockout mice inhibit signs of
inflammation and apoptosis [112]. This phenotype is
modulated by gender and age [111]. Glucose tolerance is
one of the parameters that will be carefully monitored in
the outcome trials with PCSK9 inhibitors, so far the phase
II data do not suggest the presence of this potential off-
target effect in humans.
PCSK9 in adipose tissue
PCSK9-knockout mice have more visceral adipose tissue.
Individual adipocytes are hypertrophied, most likely as a
result of increased expression of VLDLR [141].
PCSK9 and innate immune response
Pathogen-associated lipids such as lipopolysaccharide
(LPS) activate innate immune receptors inducing an
inflammatory response, e.g. during sepsis. Mammalian
lipid transfer proteins bind pathogen lipids. Interstingly,
PCSK9 inhibited LPS uptake in human liver cells [171].
Inhibition of PCSK9 improved survival and inflammation
in murine sepsis. The PCSK9 effect was abrogated in LDL
receptor (LDLR) knockout mice. These data were con-
firmed in humans with PCSK9 loss-of-function genetic
variants and in humans who are homozygous for an LDLR
variant that is resistant to PCSK9. These data suggest that
inhibition of PCSK9 mediates pathogen lipid clearance via
the LDLR regulating systemic inflammatory response.
Therapeutic strategies to inhibit PCSK9
Anti-PCSK9 antibody treatment
Fully human antibodies directed against PCSK9 have been
developed and are used in clinical trials (for detailed
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4 Page 10 of 19 Basic Res Cardiol (2015) 110:4
123
review, see [78]). These antibodies dose-dependently
reduce plasma LDL-C and also lower the plasma
Lp(a) concentration. Results of published trials are given in
Table 2. However, new strategies to modify the PCSK9-
LDLR interaction are in development (Table 3).
Partial antibodies/fragment antigen binding
Antibodies to PCSK9, binding to epitopes adjacent to the
ones required for LDLR binding, increase LDLR expres-
sion in hepatocytes. This antibody administered to mice
results in a significant reduction in plasma LDL-C con-
centration which is not seen in LDLR-knockout mice. The
effect of antibody treatment on LDL-C is even more pro-
nounced and prolonged in monkeys [30]. Similar results
are obtained with antibodies covering the catalytic domain
of PCSK9 otherwise binding the EGF-A domain of the
LDLR [119, 180]; such treatment reduces the free plasma
PCSK9 and LDL-C concentrations in rhesus monkeys
[146]. Similarly, antibodies against the C-terminal domain
lower LDL-C in cynomolgus monkeys [145].
Similar to antibodies, molecular scaffolds binding to
PCSK9 close to its LDLR binding epitopes reduce the free
PCSK9 and subsequently the LDL-C concentration in
cynomolgus monkeys [118]. Such a molecular scaffold is
adnectin (11 kDa), which is derived from human
fibronectin.
Apart from the interaction with secreted PCSK9, inter-
ference can occur at the gene or mRNA level. Induction of
loss-of-function mutations in mice, using clustered regu-
larly interspaced short palindromic repeats (CRISPR-Cas9)
genome editing, results in reduced plasma PCSK9 and
LDL-C concentrations [155]. RNA interfering (RNAi)
drugs attenuate PCSK9 synthesis and decrease plasma
PCSK9 and LDL-C concentrations in rodents [58],
primates [58] and healthy volunteers [56]. Locked nucleic
acid (LNA) antisense oligonucleotide silences PCSK9
in vitro (hepatocytes) and in vivo (mice) subsequently
reducing plasma PCSK9 and LDL-C concentrations [65].
Again, similar results are obtained in non-human primates
where a single injection of LNA decreases LDL-C con-
centration for more than 4 weeks [103].
PCSK9 has both intracellular and extracellular func-
tions which differ related to the cell type and organ.
PCSK9 affects both receptor expression and intracellular
enzyme function. Thus, antibodies directed against the
secreted form of PCSK9—acting mainly extracellu-
larly—will most likely lead to different results when
compared to approaches resulting to LOF-mutation or
gene knockout of PCSK9, both interfering PCSK9
intracellular and extracellular function. Epidemiological
findings related to GOF- or LOF- mutations of PCSK9
may therefore not easily be transferred to recent antibody
approaches.
In conclusion, effects of PCSK9 inhibitors in addition to
the regulation of the LDLR expression clearly exist and
may be beneficial. In the large on-going phase 3 programs
using PCSK9 inhibitors, to date no ‘‘loss of safety’’- signal
has been observed. The primary effect of PSCK9 inhibition
appears to be the up-regulation of hepatic LDLR but fur-
ther basic science and clinical research will advance our
understanding of how PCSK9 inhibition interferes with
lipoprotein metabolism and improve cardiovascular
outcome.
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Table 3 PCSK9 inhibitors in development
Type Compound Company Phase Comments
mAb Evolocumab AMG145 Amgen 3 PROFICIO
Alirocumab REGN7272/SAR236553 Sanofi/regeneron 3 ODYSSEY
Bococizumab RN-316;PF-04950615 Pfizer/rinat 3 SPIRE
RG7652 Roche/genentech 2 On hold
LY3015014 Eli Lilly 2
LGT209 Novartis 2
Adnectin Ad. BMS-962476 BMS-Adnexus 2
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